Zurück

Wählen Sie Ihre Region

Corporate

Europa:

Flagge Albanien Albanien Flagge Bosnien-Herzegowina Bosnien-Herzegowina Flagge Bulgarien Bulgarien Flagge Kroatien Kroatien Flagge Zypern Zypern Flagge Montenegro Montenegro Flagge Tschechien Tschechien Flagge Dänemark Dänemark Flagge Estland Estland Flagge Spanien Spanien Flagge Kosovo Kosovo Flagge Litauen Litauen Flagge Lettland Lettland Flagge Luxemburg Luxemburg Flagge Mazedonien Mazedonien Flagge Deutschland Deutschland Flagge Polen Polen Flagge Portugal Portugal Flagge Rumänien Rumänien Flagge Serbien Serbien Flagge Slowakei Slowakei Flagge Slowenien Slowenien Flagge Schweiz Schweiz Flagge Schweden Schweden Flagge Türkei Türkei Flagge Ungarn Ungarn Flagge Großbritannien Großbritannien Flagge Italien Italien

Asien:

Flagge UAE UAE Flagge Hong Kong Hong Kong Flagge Kuwait Kuwait Flagge Libanon Libanon

Afrika:

Flagge Südafrika Südafrika

Vereinbaren Sie ein Beratungsgespräch über Stammzellen

Mehr erfahren

Kontaktieren Sie uns noch heute!

Möchten Sie mehr über unsere Dienstleistungen erfahren? Füllen Sie das untenstehende Formular aus, und wir werden uns so schnell wie möglich mit Ihnen in Verbindung setzen, um Ihnen alle notwendigen Informationen zu geben und Ihre Fragen zu beantworten.

    Wir möchten Sie darauf hinweisen, dass die im Formular angegebenen personenbezogenen Daten von FamiCord Suisse mit Sitz in der Schweiz (BusinessPark Zug Sumpfstrasse 26, 6302 Zug) zur telefonischen Kontaktaufnahme im Zusammenhang mit der Erteilung von Serviceinformationen verarbeitet werden.

    Obraz

    Unsere
    Transplantationen

    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:

    Obraz
    Liste der Verwendungen von Stammzellen, die von den Laboren der FamiCord-Gruppe freigegeben wurden:
    Nr. Quelle Quellentyp Diagnose Medizinbereich Anwendungsjahr Therapie Land Alter des Empfängers
    1001 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
    1002 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 66
    1003 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
    1004 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 60
    1005 Apheresis Allogeneic Fanconi's Anemia Hematology 2025 Standard Therapy Ukraine 6
    1006 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 69
    1007 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
    1008 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Macedonia 56
    1009 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy CROATIA 64
    1010 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 75
    1011 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy NETHERLANDS 65
    1012 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
    1013 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Brazil 48
    1014 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 17
    1015 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy United Kingdom 13
    1016 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 69
    1017 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 13
    1018 Apheresis Allogeneic B-cell Precursor Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Slovakia 67
    1019 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 72
    1020 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 52
    1021 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 64
    1022 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Italy 68
    1023 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 56
    1024 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
    1025 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 55
    1026 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
    1027 Apheresis Allogeneic Myelodysplastic disorder Hematology 2025 Standard Therapy France 63
    1028 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
    1029 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 20
    1030 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 23
    1031 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 73
    1032 Apheresis Allogeneic Inherited Immune System Disorder Hematology 2025 Standard Therapy France 9
    1033 Apheresis Allogeneic Lymphoma – DLBCL Hematology 2025 Standard Therapy United Kingdom 55
    1034 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 61
    1035 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Lithuania 58
    1036 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 73
    1037 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 35
    1038 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2025 Standard Therapy Germany 65
    1039 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
    1040 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 66
    1041 Apheresis Autologous Diffuse large B-cell lymphoma Hematology 2025 Standard Therapy Germany 42
    1042 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Netherlands 65
    1043 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 60
    1044 Apheresis Allogeneic Post Mielofibrosis Hematology 2025 Standard Therapy Poland 66
    1045 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 74
    1046 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 17
    1047 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 72
    1048 Apheresis Allogeneic T-cell prolymphocytic leukemia Hematology 2025 Standard Therapy New Zealand 64
    1049 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
    1050 Apheresis Allogeneic Mielofibrosis Hematology 2025 Standard Therapy Finland 68
    1051 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 35
    1052 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 34
    1053 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 63
    1054 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Poland 72
    1055 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Switzerland 69
    1056 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 52
    1057 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 26
    1058 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 50
    1059 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Poland 71
    1060 Apheresis Allogeneic Anaplastic Large Cell Lymphoma Hematology 2025 Standard Therapy Germany 3
    1061 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 71
    1062 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 29
    1063 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 38
    1064 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Poland 28
    1065 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 46
    1066 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Spain 28
    1067 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Slovakia 52
    1068 Apheresis Allogeneic T-NHL Angioimmunoblastic T-cell Lymphoma Hematology 2025 Standard Therapy Germany 56
    1069 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
    1070 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 23
    1071 Apheresis Allogeneic Mielodysplastic syndrome Hematology 2025 Standard Therapy Spain 69
    1072 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Brazil 71
    1073 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 36
    1074 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 58
    1075 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Germany 68
    1076 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 61
    1077 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 35
    1078 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 39
    1079 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Serbia 58
    1080 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 47
    1081 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Netherlands 62
    1082 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 69
    1083 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy United Kingdom 35
    1084 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 71
    1085 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 70
    1086 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
    1087 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 71
    1088 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 39
    1089 Apheresis Autologous Primary central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
    1090 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2025 Standard Therapy Germany 56
    1091 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 65
    1092 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Germany 65
    1093 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 60
    1094 Apheresis Autologous Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 32
    1095 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2025 Standard Therapy Germany 67
    1096 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 56
    1097 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Columbia 62
    1098 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 46
    1099 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 66
    1100 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 46